Skip to main content
Addgene
Showing: 21 - 38 of 38 results

  1. pAAV-hSyn-EGFP (AAV Retrograde)

    Viral Prep
    #50465-AAVrg
    Purpose
    Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. Synapsin-driven EGFP-expression control. These AAV preparations are suitable purity for injection into animals. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons.
    Depositor
    Bryan Roth
    Promoter
    Syn
    Tags
    EGFP
    Available since
    Oct. 19, 2017
    Availability
    Academic Institutions and Nonprofits only

  2. pAAV-CaMKIIa-EGFP (AAV PHP.eB)

    Viral Prep
    #50469-PHPeB
    Purpose
    Ready-to-use AAV PHP.eB particles produced from pAAV-CaMKIIa-EGFP (#50469). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-EGFP plasmid DNA. CamKIIa-driven EGFP expression control. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Bryan Roth
    Promoter
    CaMKII
    Tags
    EGFP
    Available since
    Feb. 16, 2024
    Availability
    Academic Institutions and Nonprofits only

  3. pAAV-CaMKIIa-EGFP (AAV Retrograde)

    Viral Prep
    #50469-AAVrg
    Purpose
    Ready-to-use AAV Retrograde particles produced from pAAV-CaMKIIa-EGFP (#50469). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-EGFP plasmid DNA. CamKIIa-driven EGFP expression control. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Bryan Roth
    Promoter
    CaMKII
    Tags
    EGFP
    Available since
    Sept. 13, 2021
    Availability
    Academic Institutions and Nonprofits only

  4. pAAV-CAG-GFP (AAV Retrograde trial size)

    Viral Prep
    #37825-AAVrg.T
    Purpose
    Ready-to-use AAV Retrograde trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. GFP expression control. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Edward Boyden
    Promoter
    CAG
    Tags
    GFP
    Available since
    July 12, 2019
    Availability
    Academic Institutions and Nonprofits only

  5. pAAV-hSyn-Flex-Axon-EGFP (AAV1)

    Viral Prep
    #135429-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV-hSyn-Flex-Axon-EGFP (#135429). In addition to the viral particles, you will also receive purified pAAV-hSyn-Flex-Axon-EGFP plasmid DNA. Syn-driven, Cre-dependent expression of axon-targeted EGFP control. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Rylan Larsen
    Promoter
    Syn
    Tags
    EGFP (Cre-dependent)
    Available since
    March 19, 2021
    Availability
    Academic Institutions and Nonprofits only

  6. pAAV_hSyn-SIO-stChrimsonR-EGFP-P2A-PdCO-miniWPRE (AAV5)

    Viral Prep
    #202199-AAV5
    Purpose
    Ready-to-use AAV5 particles produced from pAAV_hSyn-SIO-stChrimsonR-EGFP-P2A-PdCO-miniWPRE (#202199). In addition to the viral particles, you will also receive purified pAAV_hSyn-SIO-stChrimsonR-EGFP-P2A-PdCO-miniWPRE plasmid DNA. Synapsin-driven, Cre-dependent expression of bicistronically soma-targeted ChrimsonR in frame with EGFP and the optimized opsin PdCO. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Ofer Yizhar
    Article
    Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s
    Promoter
    Syn
    Tags
    EGFP
    Available since
    April 10, 2024
    Availability
    Academic Institutions and Nonprofits only

  7. pAAV_hSyn-SIO-stChrimsonR-EGFP-P2A-PdCO-miniWPRE (AAV1)

    Viral Prep
    #202199-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV_hSyn-SIO-stChrimsonR-EGFP-P2A-PdCO-miniWPRE (#202199). In addition to the viral particles, you will also receive purified pAAV_hSyn-SIO-stChrimsonR-EGFP-P2A-PdCO-miniWPRE plasmid DNA. Synapsin-driven, Cre-dependent expression of bicistronically soma-targeted ChrimsonR in frame with EGFP and the optimized opsin PdCO. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Ofer Yizhar
    Article
    Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s
    Promoter
    Syn
    Tags
    EGFP
    Available since
    April 10, 2024
    Availability
    Academic Institutions and Nonprofits only

  8. pAAV.GfaABC1D.PI.Lck-GFP.SV40 (AAV5)

    Viral Prep
    #105598-AAV5
    Purpose
    Ready-to-use AAV5 particles produced from pAAV.GfaABC1D.PI.Lck-GFP.SV40 (#105598). In addition to the viral particles, you will also receive purified pAAV.GfaABC1D.PI.Lck-GFP.SV40 plasmid DNA. GfaABC1D-driven GFP expression control. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Baljit Khakh
    Article
    Shigetomi et al J Gen Physiol. 2013 Apr 15.
    Promoter
    GfaABC1D
    Tags
    GFP
    Available since
    March 8, 2018
    Availability
    Academic Institutions and Nonprofits only

  9. pAAV-S5E2-GFP-fGFP (AAV9)

    Viral Prep
    #135631-AAV9
    Purpose
    Ready-to-use AAV9 particles produced from pAAV-S5E2-GFP-fGFP (#135631). In addition to the viral particles, you will also receive purified pAAV-S5E2-GFP-fGFP plasmid DNA. Bicistronic expression of GFP and membrane-targeted GFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Jordane Dimidschstein
    Article
    Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.
    Promoter
    Tags
    EGFP
    Available since
    Sept. 27, 2023
    Availability
    Academic Institutions and Nonprofits only

  10. pAAV-S5E2-GFP-fGFP (AAV1)

    Viral Prep
    #135631-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV-S5E2-GFP-fGFP (#135631). In addition to the viral particles, you will also receive purified pAAV-S5E2-GFP-fGFP plasmid DNA. Bicistronic expression of GFP and membrane-targeted GFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Jordane Dimidschstein
    Article
    Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.
    Promoter
    Tags
    EGFP
    Available since
    Sept. 15, 2021
    Availability
    Academic Institutions and Nonprofits only

  11. pAAV-S5E2-GFP-fGFP (AAV PHP.eB)

    Viral Prep
    #135631-PHPeB
    Purpose
    Ready-to-use AAV PHP.eB particles produced from pAAV-S5E2-GFP-fGFP (#135631). In addition to the viral particles, you will also receive purified pAAV-S5E2-GFP-fGFP plasmid DNA. Bicistronic expression of GFP and membrane-targeted GFP under the control of the E2 regulatory element. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Jordane Dimidschstein
    Article
    Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.
    Promoter
    Tags
    EGFP
    Available since
    Nov. 29, 2021
    Availability
    Academic Institutions and Nonprofits only

  12. pAAV-Syn-Chronos-GFP (AAV Retrograde)

    Viral Prep
    #59170-AAVrg
    Purpose
    Ready-to-use AAV Retrograde particles produced from pAAV-Syn-Chronos-GFP (#59170). In addition to the viral particles, you will also receive purified pAAV-Syn-Chronos-GFP plasmid DNA. Chronos-GFP under the control of the Synapsin promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Edward Boyden
    Article
    Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:
    Promoter
    Syn
    Tags
    GFP
    Available since
    Oct. 3, 2017
    Availability
    Academic Institutions and Nonprofits only

  13. AAV pCAG-FLEX-EGFP-WPRE (AAV5)

    Viral Prep
    #51502-AAV5
    Purpose
    Ready-to-use AAV5 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Hongkui Zeng
    Article
    Oh et al Nature. 2014 Apr 10;508(7495):207-14. do
    Promoter
    CAG
    Tags
    EGFP (Cre-dependent)
    Available since
    Oct. 3, 2019
    Availability
    Academic Institutions and Nonprofits only

  14. AAV pCAG-FLEX-EGFP-WPRE (AAV2)

    Viral Prep
    #51502-AAV2
    Purpose
    Ready-to-use AAV2 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Hongkui Zeng
    Article
    Oh et al Nature. 2014 Apr 10;508(7495):207-14. do
    Promoter
    CAG
    Tags
    EGFP (Cre-dependent)
    Available since
    March 7, 2018
    Availability
    Academic Institutions and Nonprofits only

  15. AAV pCAG-FLEX-EGFP-WPRE (AAV1)

    Viral Prep
    #51502-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Hongkui Zeng
    Article
    Oh et al Nature. 2014 Apr 10;508(7495):207-14. do
    Promoter
    CAG
    Tags
    EGFP (Cre-dependent)
    Available since
    March 7, 2018
    Availability
    Academic Institutions and Nonprofits only

  16. AAV pCAG-FLEX-EGFP-WPRE (AAV9)

    Viral Prep
    #51502-AAV9
    Purpose
    Ready-to-use AAV9 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Hongkui Zeng
    Article
    Oh et al Nature. 2014 Apr 10;508(7495):207-14. do
    Promoter
    CAG
    Tags
    EGFP (Cre-dependent)
    Available since
    March 8, 2018
    Availability
    Academic Institutions and Nonprofits only

  17. AAV pCAG-FLEX-EGFP-WPRE (AAV8)

    Viral Prep
    #51502-AAV8
    Purpose
    Ready-to-use AAV8 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre-dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Hongkui Zeng
    Article
    Oh et al Nature. 2014 Apr 10;508(7495):207-14. do
    Promoter
    CAG
    Tags
    EGFP (Cre-dependent)
    Available since
    Jan. 26, 2021
    Availability
    Academic Institutions and Nonprofits only

  18. AAV pCAG-FLEX-EGFP-WPRE (AAV Retrograde)

    Viral Prep
    #51502-AAVrg
    Purpose
    Ready-to-use AAV Retrograde particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre-dependent EGFP expression control. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Hongkui Zeng
    Article
    Oh et al Nature. 2014 Apr 10;508(7495):207-14. do
    Promoter
    CAG
    Tags
    EGFP (Cre-dependent)
    Available since
    June 15, 2020
    Availability
    Academic Institutions and Nonprofits only
Showing: 21 - 38 of 38 results